Benefits
Upper Respiratory Tract Comfort
Multiple randomized controlled trials of Wellmune have reported reductions in upper respiratory tract symptom days during periods of physical or psychological stress. This supports its use as a daily immune-defense ingredient during cold and flu season.
Athletic Recovery Support
In marathoners and other endurance athletes, Wellmune has been associated with fewer cold and flu symptom days and improved mood during the demanding post-event recovery window, when transient immune suppression is well documented.
Mucosal Immune Support
Wellmune supplementation has been associated with increases in salivary IgA following intense exercise. Salivary IgA is a key first-line mucosal defense, and its support is a plausible mechanism behind reductions in upper respiratory symptoms.
Stress and Mood During High Demand
Controlled studies in stressed women and other adults have reported improvements in global mood state and reductions in upper respiratory symptoms during periods of moderate-to-high psychological stress.
Innate Immune Priming
Wellmune binds dectin-1 receptors on innate immune cells and primes neutrophil and macrophage activity, providing a mechanistic rationale for the URTI and salivary IgA results observed in clinical trials.
Mechanism of action
Dectin-1 Receptor Binding
Beta-1,3/1,6-D-glucan from baker's yeast is recognized by the dectin-1 receptor on innate immune cells, particularly macrophages and neutrophils. This receptor engagement primes downstream immune responses to subsequent pathogenic challenges.
Innate Immune Cell Priming
After absorption via gut-associated lymphoid tissue, beta-glucan particles are taken up by macrophages and trafficked to bone marrow, spleen and lymph nodes, where they prime neutrophils and other phagocytes for more effective response to pathogens.
Mucosal IgA Support
Clinical and preclinical work indicates Wellmune supports the maintenance of salivary IgA during the immune-suppressive window that follows intense exercise, helping preserve first-line mucosal defense in the upper respiratory tract.
Cytokine and Monocyte Response
Post-exercise studies report Wellmune-associated increases in pro-inflammatory monocyte concentrations and LPS-stimulated cytokine responses, consistent with a primed but regulated innate immune system rather than indiscriminate activation.
Clinical trials
Systematic review and meta-analysis of 13 randomized controlled trials of yeast beta-glucan for prevention and treatment of upper respiratory tract infections in healthy subjects. Outcomes: URTI incidence, episode frequency, duration and symptom severity.
13 RCTs in healthy adults across multiple ages and stress contexts.
Yeast beta-glucan significantly reduced the incidence of URTIs versus placebo (OR 0.345), and reduced average number of episodes, duration of URTIs and symptom severity. The intervention was well tolerated. Authors call for more high-quality trials but conclude effects on URTIs are favorable.
Placebo-controlled trial of 250 mg or 500 mg Wellmune daily for 4 weeks post-marathon in 75 runners. Outcomes: upper respiratory tract symptom severity, duration and mood state.
75 marathon runners (35 men, 40 women), aged 18-53.
Wellmune supplementation reduced total severity and duration of upper respiratory tract symptoms during the post-marathon period versus placebo and improved mood-state scores, supporting its use as a recovery-window immune-support ingredient in endurance athletes.
Two-experiment study: (1) 182 marathon runners taking 250 mg/day Wellmune; (2) 60 cyclists taking 250 mg/day Wellmune for 10 days before strenuous cycling. Outcomes: cold/flu symptom days and salivary IgA response.
242 total participants across both experiments.
In the marathon study, Wellmune was associated with a 37% reduction in cold/flu symptom days post-event. In the cycling study, Wellmune was associated with a 32% increase in salivary IgA 2 hours post-exercise versus placebo. Together the findings support both symptomatic and mucosal immune effects.